invest summari beat ahead import pipelin data
improv earn visibl reiter ow rate price target
share think respect earn growth driven innov
medicin pipelin advanc return capit sharehold
industri averag underappreci therefor multipl
expans upward earn revis drive share higher
 takeaway support posit thesi report
revenu reflect oper growth driven
oper growth biopharmaceut group oper
growth upjohn return directli
sharehold combin dividend share
repurchas remain share repurchas author
sale driven primarili eliqui ibranc prevnar
prevenar xeljanz well strong oper growth certain
upjohn brand primarili china new commerci structur
design maxim revenu growth opportun transit
period expect sustain mid-single-digit oper
revenu growth rest expect us
approv tafamidi bavencio inlyta treatment rcc well
biosimilar rituximab bevacizumab adalimumab also
anticip phase readout inhibitor moderate-
to-sever ad rivipansel vaso-occlus crisi sickl cell diseas
busi develop front note primari potenti
area interest product offer signific advantag standard care
if/when launch tafamidi focus creat suspicion
diseas cardiologist patient educ also need
increas util non-invas method scintigraphi
diagnosi note xalkori launch diagnosi rate
mutat today
report adjust dilut ep factset
consensu higher estim rais ep guidanc
factset consensu adjust
financi model report increas ep
 valuat use blend dcf multipl ev/ebitda analysi get
price target
disclosur section may found page
use blend dcf multipl ev/ebitda analysi get price
target
sever potenti risk invest thesi price target
product repres signific portion sale could face gener
competit current portfolio product may face competit cannib
pipelin introduct new competit could diminish price
power exist drug record direct product and/or allianc revenu
billion nine biopharmaceut product prevnar lyrica
ibranc eliqui enbrel lipitor xeljanz viagra sutent account total
revenu product pfizer major product subject
problem loss patent protect applic chang prescript growth rate
affect doctor patient confid pressur exist competit product chang
label access pressur new more-effect treatment introduc
advers impact revenu could signific
pipelin delay failur and/or higher-than-forecast competit gener
may continu face access challeng biosimilar product market
biosimilar product may receiv access pariti innov product remain
disadvantag posit exampl inflectra/remsima experienc access challeng
risk relat strateg acquisit success acquisit hospira
anacor mediv astrazeneca small molecul anti-infect busi depend
larg part compani abil realiz anticip benefit combin
busi exist segment exampl may fail achiev anticip
cost save acquisit hospira cost save within expect time
frame accret impact anticip acquisit hospira anacor
mediv may realiz may delay also may fail gener revenu
growth acquir busi expect time enter transact
bull bear base case analysi
also use blend dcf multipl ev/ebitda analysi arriv bull bear case
scenario base analysi estim likelihood stock worth next month
exhibit bull bear base case scenario analysi
cantor fitzgerald research compani reportsbul casesal ibranc eliqui xeljanzand key drug exceed expectationspipelin advanc exceed expectationsstrateg accret scenario casesal ibranc eliqui xeljanzand key drug in-lin expectationspipelin advanc line expectationsno scenario casesal ibranc eliqui xeljanzand key drug expectationspipelin advanc expectationsno scenario exhibit varianc analysi
amount chang yoyamount chang yoyvariancecommentstot driven eliqui ibranc prevnar xeljanz upjohn growth emerg market gross oper non oper pre-tax tax net dilut share adjust dilut cantor fitzgerald research compani reportsactualcantor exhibit catalyst event calendar
datedriverupcom talazoparib beti first dose phase trial la/mtnbc abrocitinib phase jade moder sever ad top-line readoutjun mini-dystrophin gene therapi phase earli data duchenn muscular dystrophi boy ppmdjune avelumab inlyta axitinib action date javelin renal rcc june pembrolizumab inlyta axitinib pdufa acip vote mainten year older recommend loss biosimilar bevacizumab bsufa multival pneumococc conjug vaccin phase infant proof-of-concept readoutjuli meglumin form mg capsul pdufa biosimilar rituximab bsufa avelumabiniti phase trial head neck squamou cell talazoparib comboiniti phase trial enzalutamid comboiniti phase trial biosimilar trazimera eu japan biosimilarjapan adalimumab biosimilar bsufa adalimumab biosimilar japan coagul factor ix gene therapi initi pivot phase hemophilia data vaso-occlus crisi hospit subject sickl cell top-line readout clbp studi palbociclib ibranc present preliminari phase data healthcar businessclos transact gsk fall abrocitinib phase jade moder sever ad top-line readoutnovemb free acid form mg capsul pdufa datedecemb vaccinephas data respiratori syncyti viru decemb multival pneumococc conjug vaccin estimate primari complet date phase trial adult year age older decemb multival pneumococc conjug vaccin estimate primari complet date phase trial year data evalu next step oa china lorlatinib eu approv previously-tr alk advanc biosimilar rituximab safeti efficaci result phase data javelin lung data nsclc therapeuticsent phase partial agonist parkinson diseas symptom late data bladder mainten end inject businessexpect suppli constraint issu significantli improvedbi end xeljanz complet safeti evalu ra indic prophylact vaccin phase data invas group streptococcu data rheumatoid updat patent isavuconazol addit launchessourc cantor fitzgerald research compani report exhibit catalyst event calendar continu
datedriverupcom avelumab best support care phase javelin bladder data bladder mainten javelin gastric data gastric mainten chemo januari multival pneumococc conjug vaccin estimate primari complet date pivot phase trialapril anti data atop month stay expiresnovemb patent palbociclib phase patina data breast tfpi mab phase data hemophilia data crohn talazoparib avelumabphas javelin parp medley data local advanc metastat solid talazoparib phase data metastat data activ non-segment therapeut vaccin phase data vaccine-bas immunotherapi regimen prostat data moder sever ulcer prophylact vaccin phase clover data clostridium difficil data ankylos enzalutamid leuprolidephas embark data nonmetastat hspc palbociclib phase penelop data high-risk earli breast palbociclib phase palla data intermediate-risk earli breast end multival pneumococc conjug vaccin potenti file adult earli readout cancer pain studi asept process map facilitycomplet construct portag combo w/ soc chemoradi crt phase javelin head neck data head neck talazoparib avelumabphas javelin brca/atm data metastat solid tumor brca atm eu patent eu patent oral inhibitor phase pivot readout alopecia areata end co-promot talazoparib w/ novel hormon therapi nht phase data metastat castration-resist patent patent palbociclib us/major eu/japan patent palbociclib major eu patent adalimumab biosimilar licens period begin per agreement asept process map facilitybegin product portag patent patent eu/japan patent patent eu patent patent eu/japan patent eu patent enzalutamid us patent patent eu patent patent patent patent patent talazoparib us patent expir file extend actual ext grant could avelumab major eu/japan patent avelumab us patent lorlatinib us patent expirationsourc cantor fitzgerald research compani report exhibit cantor estim versu manag guidanc
exhibit incom statement analysi
exhibit margin analysi
exhibit quarterli sale analysi
exhibit annual sale analysi
exhibit analysi
exhibit balanc sheet analysi
pfizer inc engag discoveri develop manufactur healthcar product
